Hematology
Board Certified in 2008
Oncology
Board Certified in 2007
Hematology
Board Certified in 2008
Oncology
Board Certified in 2007
Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010
Medical School
Harvard Medical School, Boston, MA
Residency
Department of Medicine, Brigham and Women’s Hospital, Boston, MA
Fellowship
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
Bryn Mawr Hospital
Lankenau Hospital
Paoli Hospital
Attending Physician
CD40 antibody for the treatment of advanced solid tumors (Phase I study), PI: Robert Vonderheide, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006
CTLA4 antibody in the treatment of advanced breast cancer (Phase I study), PI: Susan Domchek, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006
The use of executive summaries in cancer patients’ consent to clinical trial enrollment (Phase II study), PI: Jane Weeks, M.D. and Steven Joffe, M.D., Dana Farber Cancer Institute, 2003
Vonderheide, RH, Flaherty KT, Khalil M, Stumacher MS, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.
Stumacher, M, Domchek S. Update on chemoprevention in BRCA1and BRCA2 mutation carriers. Breast Cancer Online. 2005 Vol. 8 Issue 9.
Let’s get started! Answer a few basic questions to see if Jumpstart© with OPTIFAST® Program is right for you.
